Io Biotech Posts Wider Loss in Q2

Io Biotech's Q2 2025 results revealed its lead cancer vaccine candidate, Cylembio®, demonstrated clinical improvement in progression-free survival for advanced melanoma in its pivotal Phase 3 trial, but critically missed the primary endpoint for statistical significance (p=0.056 vs. threshold p≤0.045). This statistical miss jeopardizes immediate regulatory approval, prompting planned discussions with the FDA. Financially, the company reported a widened GAAP net loss of $26.2 million and utilized $9.0 million in cash, ending the quarter with $28.1 million in cash and equivalents. A post-quarter EIB loan extends its cash runway into Q1 2026, highlighting ongoing funding dependence and the heightened focus on regulatory outcomes and future capital needs.

Analysis

IO Biotech's Q2 2025 results are overshadowed by the pivotal Phase 3 trial for its lead candidate, Cylembio®, which narrowly missed its primary endpoint for statistical significance with a p-value of 0.056 against a required threshold of p≤0.045. This failure significantly jeopardizes the path to regulatory approval, despite the trial demonstrating a clinical benefit in progression-free survival (19.4 months vs. 11.0 months for the control). The company's financial position is increasingly tenuous, marked by a widening GAAP net loss of $26.2 million, which exceeded estimates, and a quarterly cash burn of $9.0 million, leaving it with $28.1 million in cash. While a post-quarter loan of approximately $13.7 million extends the operational runway, it only lasts into Q1 2026, creating a significant financing overhang. The absence of forward guidance amplifies uncertainty, placing immense pressure on the upcoming FDA discussions in fall 2025, which will be the primary determinant of the company's near-term viability and Cylembio's future.

Key Decisions for Investors

• The investment thesis for IO Biotech has become a high-risk, binary event centered on the upcoming FDA meeting; the stock should be considered speculative, pending clarity on a viable regulatory path for Cylembio®.
• Given the limited cash runway extending only into Q1 2026 and ongoing cash burn, investors should anticipate a high probability of a dilutive financing event within the next two to three quarters, irrespective of trial outcomes.
• Monitor for two key catalysts: the outcome of the FDA meeting in fall 2025, which is the primary value driver, and the pipeline data readouts in H2 2025, which could provide secondary valuation support but are unlikely to offset a negative Cylembio® regulatory decision.